Press release
Fabry Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Protalix Biotherapeutics, Sanofi, 4D Molecular therapeutics, Ozmosis Research, AvroBio, Freeline Therapeutics and Others.
Fabry Disease Pipeline
Fabry Disease can have many symptoms because it affects cells throughout the body. The symptoms include: Chronic pain - usually a burning or tingling sensation - in the hands and feet, Clusters of small, dark red spots in various locations on the skin, Opaque corneas, resulting in cloudy-looking eyes and problems with eyesight, Ringing in the ears, and hearing loss. Fabry Disease is caused by a mutation of the GLA gene, which encodes for the alpha-galactosidase A enzyme. The mutation usually makes the enzyme unable to function, although in mild cases, it may function to some degree. The disease is inherited in an X-linked dominant manner, which means that the gene involved is situated on the X chromosome.
To know more about Fabry Disease, please click here: https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's, "Fabry Disease Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fabry Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for Free Sample Pages: https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of Fabry Disease Companies are:
• Protalix Biotherapeutics
• Sanofi
• 4D Molecular therapeutics
• Ozmosis Research Inc.
• AvroBio
• Freeline Therapeutics
• Sangamo Therapeutics
• Translate Bio
• Abeona Therapeutics
• AVROBIO
• Sangamo Therapeutics
• And Many Others
DelveInsight's Fabry Disease report covers around 15+ products under different phases of clinical development like:
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Request for Free Sample Pages: Request for Free Sample Pages: https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of Fabry Disease Drugs are:
• Venglustat
• Pegunigalsidase alfa
• 4D 310
• And Many Others
Fabry Disease Report Key Questions:
• How many companies are developing Fabry Disease drugs?
• How many Fabry Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fabry Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fabry Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fabry Disease and their status?
• What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Pages: https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents:
Introduction
Executive Summary
Fabry Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Fabry Disease - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Fabry Disease companies' collaborations, Licensing, Acquisition -Deal Value Trends
Fabry Disease Collaboration Deals
Late Stage Products (Preregistration)
Pegunigalsidase alfa: Protalix Biotherapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Venglustat: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
4D 310: 4D Molecular Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Fabry Disease Key Companies
Fabry Disease Key Products
Fabry Disease- Unmet Needs
Fabry Disease- Market Drivers and Barriers
Fabry Disease- Future Perspectives and Conclusion
Fabry Disease Analyst Views
Fabry Disease Key Companies
Appendix
Request for Deatiled TOC: Request for Free Sample Pages: https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Protalix Biotherapeutics, Sanofi, 4D Molecular therapeutics, Ozmosis Research, AvroBio, Freeline Therapeutics and Others. here
News-ID: 2663080 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Fabry
Key Factor Supporting Global Fabry Disease Treatment Market Development in 2025: …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Fabry Disease Treatment Market Size By 2025?
The valuation of the Fabry disease treatment market has experienced robust expansion recently, projected to advance from $2.09 billion in 2024 up to $2.27 billion by 2025, reflecting an 8.8% compound annual growth rate during this timeframe. This…
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
